Home @CovidAnalysis Meta Analysis 266 ivermectin COVID-19 studies, 208 peer reviewed, 105 comparing treatment and control groups. *Recent: Ulloa-Aguilar.* PRINCIPLE TOGETHER ACTIV-6 COVID-OUT. Ivermectin was adopted in all or part of 23 countries (40 including non-government medical organizations). Submit updates/corrections. Summary.

	Search		Ivermectin	All
Sep 27	Ulloa-Aguilar et al., C The National Review of the interaction between			
Sep 17	Zhu et al., The Americ Circu Investigation of the circulation			
Aug 12	Kassaee et al., Pharm Inhale In Vitro study developing iverme			
Augs	Enyeji et al., Viral Im Effect Review of the successful treatm		nt of COVID-19 Infect 0-19 using existing m	- 123
Jul 22	Covid Analysis Iverm Statistically significant lower ris		/ID-19: real-time me mortality, ventilation,	1875
52/11/5	Wijewickrema et al., Effica 51% improved viral clearance (	15	y of oral ivermectin ir 249 hospitalized pati	
V1 17>	Wimalawansa, S., He Unloc Review showing reduced effica			
71114	Shouman et al., Cell SARS Review of possible mechanisms		ciated lymphopenia: penia in SARS-CoV-2	FO 25 25
May 31 Jun 13	Hashmi et al., Critical Iverm Early terminated REMAP-CAP re			
Mays	Thorp et al., Integrativ Globa	al COVID-19 F	Pandemic Outcomes	: A Cross-Coun

Retrospective study of 108 countries showing negative correlations between hy...

**Naggie**, S., JAMA, doi... Error in the Exclusion of Participants From Analysis in... Partial correction to ACTIV-6 600 confirming that 16% of patients were missing ...

**Varnaseri** et al., Jundi... Ivermectin as a Potential Addition to the Limited Anti-... 82% lower ventilation (p=0.02), 83% lower ICU admission (p=0.0004), 33% short...

Xu et al., Pharmaceuti... Enhanced In Vitro Antiviral Activity of Ivermectin-Load... Non-COVID-19 *In Vitro* study showing enhanced antiviral activity of ivermectin a...

de Oliveira Só et al., P... In Silico Comparative Analysis of Ivermectin and Nirm... In Silico study showing that ivermectin and nirmatrelvir interact with the SARS-C...

**Scheim** et al., Viruses... Back to the Basics of SARS-CoV-2 Biochemistry: Micr... Review of the biochemical underpinnings of the severe morbidities of COVID-19,...

Shahin et al., Researc... The selective effect of Ivermectin on different human ... In Vitro study showing dose-dependent inhibition of wildtype and omicron SARS...

**Gao** et al., Internation... Ivermectin ameliorates acute myocarditis via the inhi... Mouse study showing that ivermectin improves cardiac function and reduces inf...

Agamah et al., Scienc... Network-based multi-omics-disease-drug association... In Silico study identifying potential drugs beneficial for COVID-19 by integrating t...

**Corral** et al., Global J... Early Treatment Outcomes of SARS-Cov-2 with Iverm... Retrospective 475 nursing home residents showing low mortality with early trea...

Siripongboonsitti et a... A Randomized Trial to Assess the Acceleration of Vira... 39% improved recovery (p=0.19) and 6% improved viral clearance (p=0.75). RCT ...

Yagisawa et al., The J... Global trends in clinical trials of ivermectin for COVID-... Review of global trends in clinical trials of ivermectin for COVID-19. The review s...

Jitobaom et al., Jour... Identification of inositol monophosphatase as a broa... In vitro study showing that ivermectin inhibits dengue, Zika, and SARS-CoV-2 by...

Hayward et al., Journ... Ivermectin for COVID-19 in adults in the community (...

Significantly improved recovery and significantly lower risk of long COVID with iv...

Oranu et al., GSC Biol... Validation of the binding affinities and stabilities of ive... In Silico study showing that ivermectin and moxidectin bind strongly to SARS-Co...

Mohammed et al., Eu... A remodeled ivermectin polycaprolactone-based nan... In Vitro and rat study showing that an optimized polycaprolactone-based nanop...

Fauquet et al., Molec... Microfluidic Diffusion Sizing Applied to the Study of N... *In Vitro* study showing that ivermectin modulated SARS-CoV-2 spike RBD-ACE2 i...

**Gkioulekas** et al., Pre... Critical appraisal of multidrug therapy in the ambulat... Reanalysis of 119 hypoxemic COVID-19 outpatients treated with multidrug regi...

Liu et al., Frontiers in ... Crosstalk between neutrophil extracellular traps and i... Ivermectin may be beneficial for COVID-19 ARDS by blocking GSDMD and NET f...

Vanhee et al., Drug T... Substandard and falsified ivermectin tablets obtained... Analysis of intercepted ivermectin tablets in Belgium showing 100% of 19 samp...

**Scheim** et al., Interna... Sialylated Glycan Bindings from SARS-CoV-2 Spike Pr... Review of evidence suggesting that binding of the SARS-CoV-2 spike protein to ...

Didenko, K., Zenodo, ... Novel non-covalent ivermectin complex Didenectin is ... Report on a non-covalent complex of ivermectin called Didenectin, showing imp...

Tallaksen, E., Do Your... Waiting for PRINCIPLE

Discussion of issues in the ivermectin arm of the PRINCIPLE trial [Hayward], incl...

**García-Aguilar** et al., I... In Vitro Analysis of SARS-CoV-2 Spike Protein and Iver... In Vitro analysis showing a definitive interaction between ivermectin and the spi...

Avula et al., Journal o... Strategies used for the COVID-OUT decentralized trial... Report on the operation of the COVID-OUT trial noting several issues affecting t...

**Tallaksen**, E., Do Your... TOGETHER Files 2: Lawsuit reveals FTX bought effect... Analysis of legal documents showing that a non-profit controlled by FTX's SBF a...

Lindsell et al., Journa... ACTIV-6: Operationalizing a decentralized, outpatient ...

Discussion of the operation of ACTIV-6 [Naggie] revealing participant fraud - aut...

Marinos et al., Do Yo... The TOGETHER Files 1: The Andrew Hill connection - ... Leaked documents show additional misconduct in the Together Trial [Reis]. Blin...

Hazan et al., ACG 2023 Treatment with Ivermectin Increases the Population o... Analysis of the effect of ivermectin on the gut microbiome, showing a significant...

Liu et al., Stem Cell R... SARS-CoV-2 viral genes Nsp6, Nsp8, and M compro... In Vitro study showing that ivermectin and meclizine mitigated cardiac cell deat...

**Zhao** et al., Frontiers i... Identification of the shared gene signatures between ... In Silico study identifying IGF1 as a shared gene between pulmonary fibrosis an...

Mills et al., medRxiv, ... Published benefits of ivermectin use in Itajaí, Brazil for... Highly flawed analysis with multiple basic errors, invalid assumptions, highly bia...

**Chamie** et al., Cureus... COVID-19 Excess Deaths in Peru's 25 States in 2020: ... Ecological analysis showing that ivermectin distribution correlated significantly (...

Osati et al., medRxiv, ... Clinical manifestations and mortality among hospitali... 32% lower mortality (p=0.02). Retrospective 1,387 hospitalized PCR confirmed C...

**Vottero** et al., Molecul... Computational Prediction of the Interaction of Iverme... *In Silico* study showing that ivermectin may bind with high affinity to multiple sit...

**Breitinger** et al., Virol... Patch-clamp studies and cell viability assays suggest ... In Vitro analysis of inhibitors against the SARS-CoV-2 E ion channel. - The E prot...

**Abd-Elmawla** et al., J... Suppression of NLRP3 inflammasome by ivermectin a... Animal study showing that ivermectin alleviated pulmonary inflammation and fib...

PREVENT-COVID Prophylaxis of COVID-19 Disease With Ivermectin in C... Estimated 412 participant ivermectin prophylaxis RCT with results not reported ...

**Choi** et al., Journal of ... Two Years of Experience and Methodology of Korean ... Review of the development of COVID-19 treatment guidelines in Korea. Authors ...

Wade et al., Value in ... Variation in Demographic Characteristics, Socioecon...

Retrospective analysis of mortality for COVID-19 patients in the USA. Authors do...

Yemeke et al., BMJ O... Impact of the COVID-19 pandemic on the quality of m... Review of the quality of medical products in Zimbabwe during the pandemic, no...

El-Tanani et al., Phar... Phase II, Double-Blinded, Randomized, Placebo-Contr... RCT 69 outpatients in Jordan, showing improved viral clearance and CRP with ...

Sheldrick, K., This Sc... Schedule A: Statement

Dr. Kyle Sheldrick, part of a group of researchers known for false and highly influ...

Requejo Domínguez ... Quality of clinical evidence and political justifications ... Authors' claim the first RCT was in August 2020 and did not show a benefit, ho...

Scheim et al., Journal... When Characteristics of Clinical Trials Require Per-Pr... Analysis of PP vs. ITT results in three RCTs, including discussion of multiple criti...

Wada et al., Frontiers ... Efficacy and safety of single-dose ivermectin in mild-t... 19% lower progression (p=0.46), 14% higher need for oxygen therapy (p=0.46), 2...

Llenas-García et al., ... Ivermectin Effect on In-Hospital Mortality and Need fo... 17% lower mortality (p=0.82), 18% lower need for oxygen therapy (p=0.37), 23% ...

Kory, P., International ... The Global War on Ivermectin
Review of the clinical evidence for ivermectin for COVID-19 and the methods us...

Babalola et al., Medic... The Place of Ivermectin in the Management of Covid-... Review of the clinical and epidemiological evidence of efficacy, *in vitro* and anim...

Loo et al., Pharmaceu... Recent Advances in Inhaled Nanoformulations of Vac... Review of nanoformulations for inhaled therapeutics for respiratory viral infectio...

**Munir** et al., Healthca... Clinical Disease Characteristics and Treatment Trajec... 48% lower mortality (p=0.13). Retrospective 1,000 hospitalized COVID-19 patien...

Ragó et al., GeroScie... Results of a systematic review and meta-analysis of e... Systematic review and meta analysis of trials within the first year of the pandemi...

Naggie et al., JAMA, ... Effect of Higher-Dose Ivermectin for 6 Days vs Placeb...

600µg/kg arm of ACTIV-6. Results of this trial are unreliable, with multiple critica...

Ceballos et al., Biome... Ivermectin systemic availability in adult volunteers tre... Comparison of ivermectin as an oral solution, tablets, or capsules, showing >50...

**Viglione** et al., The Ga... Intravenous high dose vitamin C and ozonated saline ... Retrospective 479 high risk outpatients in the USA treated with a protocol includ...

**Desort-Henin** et al., E... The SAIVE Trial, Post-Exposure use of ivermectin in C... 96% fewer cases (p<0.0001). PEP RCT 399 patients in Bulgaria showing significa...

**Sarojvisut** et al., Infec... An Open Label Randomized Controlled Trial of Iverme... 104% higher ICU admission (p=0.62), 104% worse improvement (p=0.62), and 4...

Galal et al., Advances... The Use of Mebendazole in COVID-19 Patients: An Ob... Retrospective 157 inpatients and 185 outpatients in Egypt, showing improved re...

**Boschi** et al., bioRxiv, ... SARS-CoV-2 Spike Protein Induces Hemagglutination:... *In Vitro* study showing that ivermectin blocked hemagglutination (clumping of re...

**De Forni** et al., PLoS ... Synergistic drug combinations designed to fully supp... Vero E6 *In Vitro* study showing ivermectin and remdesivir to be highly synergisti...

**Naggie** et al., JAMA, ... Effect of Ivermectin vs Placebo on Time to Sustained ... The ACTIV-6 trial can be found under the original release date [Naggie].

Ochoa-Jaramillo et al... Clinical efficacy and safety of ivermectin (400  $\mu$ g/kg, ... 57% lower mortality (p=0.35), 34% higher ventilation (p=0.62), and 37% higher I...

Scheim, D., Center fo... From Cold to Killer: How SARS-CoV-2 Evolved without... Review of how SARS-CoV-2 evolved to agglutinate and clot blood cells without h...

Marinos, A., Do Your ... Did Use Of Ivermectin In Latin America Sabotage Clini... Meta analysis of ivermectin trials showing community use of ivermectin in Latin ...

**Mikamo** et al., Journa... Efficacy and safety of ivermectin in patients with mild ... 205% higher progression (p=0.49), 4% worse improvement (p=0.62), and 4% im...

Sobrinho et al., Medi... Clinical protocol for early treatment of COVID-19 in a ...

Retrospective 116 patients between May and September 2020 in Brazil receivin...

Aref et al., Infection a... Possible Role of Ivermectin Mucoadhesive Nanosusp... 74% faster recovery (p=0.0005). 96 patient RCT showing faster resolution of pos...

Kory, P., Pierre Kory's ... The Criminal Censorship of Ivermectin's Efficacy By T... Review of censorship and negative publication bias for ivermectin research.

**Uematsu** et al., The J... Prophylactic administration of ivermectin attenuates ... Hamster study showing that prophylactic ivermectin inhibited COVID-19 weight ...

Akhtar et al., The Prof... Does ivermectin reduce COVID-19 mortality and prog... 90% lower mortality (p<0.0001), 72% lower ICU admission (p=0.0006), 80% high...

**Qadeer** et al., Pakista... Ivermectin A Potential Treatment In Covid-19, Related... 58% improved viral clearance (p<0.0001). Prospective convenience sampling stu...

**Gkioulekas** et al., CO... Statistical Analysis Methods Applied to Early Outpatie... Retrospective analysis of case series data from 3,164 high-risk COVID-19 outpa...

Bramante et al., NEJ... Randomized Trial of Metformin, Ivermectin, and Fluvo... COVID-OUT remote RCT, showing no significant differences compared to a com...

Kory, P., Pierre Kory's ... The Miracle Not-Heard Around The World: The Succe... Detailed review of Uttar Pradesh's use of ivermectin, the dramatically better resu...

Chellasamy et al., Jo... Docking and molecular dynamics studies of human e... In Silico study of SARS-CoV-1&2 endodomains and ezrin docking, identifying ive...

Al-kuraishy et al., Cur... Central effects of Ivermectin in alleviation of Covid-19... Review of the potential benefits of ivermectin for mitigating SARS-CoV-2 infectio...

Marcolino et al., BMC... Systematic review and meta-analysis of ivermectin fo... Meta analysis including 25 of studies (RCTs), with only 10 and 8 reporting mort...

Schilling et al., eLife, ... Pharmacometrics of high dose ivermectin in early CO... 86% lower progression (p=0.24) and 9% worse viral clearance (p=0.36). Very hig...

Hazan, S., Frontiers i... Microbiome-Based Hypothesis on Ivermectin's Mech...

Hypothesis for an additional mechanism of action for ivermectin: inhibition of pr...

Saha et al., Pharmace... Manipulation of Spray-Drying Conditions to Develop a... Development and analysis of an inhalable dry powder formulation of ivermectin....

**Elshafie** et al., Expert ... Ivermectin Role in COVID-19 Treatment (IRICT): single... This study was retracted due to data integrity and validity concerns [tandfonline....

Umar et al., Jurnal Te... Inhibitory potentials of ivermectin, nafamostat, and c... In Silico study of ivermectin, camostat, and nafamostat, showing that ivermecti...

Nimitvilai et al., Journ... A randomized controlled trial of combined ivermectin ... 33% improved viral clearance (p=0.12). RCT low-risk patients in Thailand compa...

**Mirahmadizadeh** et a... Efficacy of single-dose and double-dose ivermectin e... 67% lower ventilation (p=0.37), 46% lower hospitalization (p=0.22), and 39% imp...

Popp et al., Cochrane... Ivermectin for preventing and treating COVID-19
Highly biased meta analysis. Authors originally wrote a highly biased meta analy...

Jitobaom et al., BMC ... Synergistic anti-SARS-CoV-2 activity of repurposed a... In Vitro study showing a strong synergistic effect of combinations of ivermectin,...

**Rezai** et al., Frontiers ... Non-effectiveness of Ivermectin on Inpatients and Ou... 9% higher ICU admission (p=0.95), 36% higher hospitalization (p=0.41), 2% wors...

Rezai et al., Frontiers ... Non-effectiveness of Ivermectin on Inpatients and Ou... 31% lower mortality (p=0.36), 50% lower ventilation (p=0.07), 16% lower ICU ad...

Williams, T., Do Your ... Not All Ivermectin Is Created Equal: Comparing The Q... In Vitro analysis of ivermectin from 11 different sources showing highly variable ...

Shafiee et al., Virolog... Ivermectin under scrutiny: a systematic review and m... Meta analysis including 17 of studies (RCTs), finding significantly lower mortalit...

**Naggie** et al., JAMA, ... Effect of Ivermectin vs Placebo on Time to Sustained ... 257% higher combined mortality/hospitalization (p=0.11), 5% higher hospitalizat...

Angkasekwinai et al.,... Safety and Efficacy of Ivermectin for the Prevention a...

Low-risk RCT in Thailand with zero mortality, reporting no significant differences...

**George** et al., Indian J... Single Dose of Ivermectin is not Useful in Patients wit... 30% lower mortality (p=0.55), 19% faster recovery (p=0.37), 33% lower progressi...

Schwartz, E., New Mi... Does ivermectin have a place in the treatment of mild... Discussion of ivermectin research compared to paxlovid and molnupiravir. Auth...

de la Rocha et al., BM... Ivermectin compared with placebo in the clinical cour... 15% worse recovery (p=0.58) and 2% improved viral clearance (p=0.64). Small Io...

**Valerio Pascua** et al., ... Repurposing Drugs for Covid-19 by a Developing Cou... Review of a multiphasic multidrug early treatment protocol for COVID-19 in Hon...

Silva et al., Frontiers i... Clinical-Epidemiology Aspect of Inpatients With Mode... 32% lower mortality (p=0.57). Retrospective 395 hospitalized patients in Brazil, s...

Alvarado et al., Comp... Interaction of the New Inhibitor Paxlovid (PF-0732133... In Silico study comparing ivermectin and paxlovid M<sup>pro</sup> interaction, showing sim...

Croci et al., Internatio... Liposomal Systems as Nanocarriers for the Antiviral ... In Vitro study of liposomal formulations of ivermectin showing up to 5 times low...

**Babalola** et al., Resea... Ivermectin is associated with increase in SPO2 in hyp... Extended analysis of [Thairu], showing significantly faster and greater improvem...

Marinos, A. The Problem With The TOGETHER Trial Analysis of serious problems with the Together Trial. Also see [Marinos].

Zheng et al., Internati... Red blood cell-hitchhiking mediated pulmonary delive... In Vitro and mouse study proposing a method for improving ivermectin pharma...

Ravikirti et al., Resear... Association between Ivermectin treatment and morta... 3% lower mortality (p=0.82). Retrospective 965 late stage (44% severe, 27% ICU...

**Delandre** et al., Phar... Antiviral Activity of Repurposing Ivermectin against a ... In Vitro study with 30 COVID-19 strains from 14 variants, showing stronger effic...

Aminpour et al., Com... In Silico Analysis of the Multi-Targeted Mode of Actio...

In Silico analysis identifying strong or moderate affinity bindings for ivermectin t...

**Bitterman** et al., JAM... Comparison of Trials Using Ivermectin for COVID-19 ... Analysis of a small subset of 12 ivermectin trials showing a relationship with effi...

Albariqi et al., Interna... Pharmacokinetics and Safety of Inhaled Ivermectin in ... Mouse study of an inhaled ivermectin formulation, showing high concentrations...

Uniyal et al., Internati... Effect of Ivermectin mass drug administration on the ... Analysis of mass administration of ivermectin for COVID-19 in Uttarakhand com...

Albariqi et al., Journa... Preparation and Characterization of Inhalable Iverme... Creation and analysis of an inhalable dry powder formulation of ivermectin for C...

Harper, P. Professor tied to altered Andrew Hill paper also prepa... Forensic analysis of the Hill meta analysis discovering an unlisted author potenti...

Lawrie, T. A Letter to Dr. Andrew Hill

Documentary about the external forces changing the conclusions of the Hill et a...

Therapeutic Goods A... TGA cautions consumers over counterfeit ivermectin News release from the Australian Therapeutic Goods Administration warning ab...

Soto et al., PLOS ONE... Mortality and associated risk factors in patients hospi... 41% higher mortality (p=0.001). Retrospective 1,418 very late stage (46% mortal...

**Efimenko** et al., Intern... Treatment with Ivermectin Is Associated with Decrea... 69% lower mortality (p<0.0001). PSM retrospective 41,608 patients in the USA, ...

Thairu et al., Journal ... A Comparison of Ivermectin and Non Ivermectin Base... 88% lower mortality (p=0.12), 55% higher hospital discharge (p=0.0001), and 95...

Lim et al., JAMA, doi:... Efficacy of Ivermectin Treatment on Disease Progress... The I-TECH RCT can be found at [c19ivm.org]. Studies are listed under the date ...

Kerr et al., Cureus, do... Regular Use of Ivermectin as Prophylaxis for COVID-1... 92% lower mortality (p=0.0008). PSM multivariable analysis of the Itajaí trial sho...

Manomaipiboon et al... Efficacy and safety of ivermectin in the treatment of ...

43% improved recovery (p=0.26) and 5% improved viral clearance (p=1). Small R...

Kowa, Press Release Antiviral effect of ivermectin confirmed for omicron Kowa reports that ivermectin is effective for omicron in *In Vitro* research.

Malektojari et al., Asi... Efficacy and safety of ivermectin in patients with mild ... Small trial with 50% of patients missing without explanation. The protocol and r...

de Jesús Ascencio-... A Multimodal Strategy to Reduce the Risk of Hospitali... 59% lower combined mortality/hospitalization (p<0.0001), 15% lower mortality (...

Liu et al., Stem Cell R... Genome-wide analyses reveal the detrimental impact... In Vitro study showing that ivermectin and meclizine treatment may minimize S...

Parvez et al., Immunit... Insights from a computational analysis of the SARS-C... In Silico analysis of the omicron variant and 10 treatments reported effective for ...

**Zubair** et al., Monaldi ... The effect of ivermectin on non-severe and severe CO... 9% higher mortality (p=1) and 8% longer hospitalization (p=0.4). Retrospective 1...

Tyson et al., Roundin... Low Rates of Hospitalization and Death in 4,376 COV... 100% lower mortality (p<0.0001) and 100% lower hospitalization (p<0.0001). Ret...

Abbas et al., Indian J... The Effect of Ivermectin on Reducing Viral Symptoms... 41% lower progression (p=0.54) and 36% improved recovery (p=0.04). RCT 99 iv...

Kerr et al., ResearchG... COVID-19 In-Hospital Mortality Rate is Reduced by Pr... 45% lower mortality (p=0.05). PSM retrospective 378 hospitalized patients in Br...

Shimizu et al., Journa... Ivermectin administration is associated with lower ga... 100% lower mortality (p=0.001), 48% lower ventilation (p=0.03), 43% lower ICU ...

Semiz, S., Biomolecul... SIT1 transporter as a potential novel target in treatme... Review of the potential connections between SLC6A20/SIT1, ACE2, Type 2 Diab...

**Mustafa** et al., Explor... Pattern of medication utilization in hospitalized patien... 64% lower mortality (p=0.09). Retrospective 444 hospitalized patients in Pakista...

Baguma et al., Resear... Characteristics of the COVID-19 patients treated at G...

97% lower mortality (p=0.31). Retrospective COVID+ hospitalized patients in Uga...

**Zaidi** et al., The Journ... The mechanisms of action of ivermectin against SAR... Extensive review of 20 mechanisms of action of ivermectin for SARS-CoV-2.

Therapeutic Goods A... TGA warns about imports of ivermectin News release from the Australian Therapeutic Goods Administration warning ab...

Jamir et al., Cureus, ... Determinants of Outcome Among Critically III Police P... 53% higher mortality (p=0.13). Retrospective 266 COVID-19 ICU patients in India...

Kerr et al., Cureus, do... Ivermectin Prophylaxis Used for COVID-19: A Citywid... 70% lower mortality (p<0.0001), 67% lower hospitalization (p<0.0001), and 44% ...

**Wentzel** et al., Open F... Systematic Review and Meta-Analysis of Ivermectin S... Systematic review and meta-analysis of safety in ivermectin COVID-19 trials, sh...

Behl et al., Science of... CD147-spike protein interaction in COVID-19: Get the ... Review of the cluster of differentiation 147 (CD147) transmembrane protein as a...

Ferreira et al., Revista... Outcomes associated with Hydroxychloroquine and I... 54% higher combined mortality/intubation (p=0.37). Retrospective 230 hospitali...

Ozer et al., Journal of... Effectiveness and Safety of Ivermectin in COVID-19 P... 75% lower mortality (p=0.09), 13% lower ventilation (p=0.2), and 9% longer hosp...

Samajdar et al., Jour... Ivermectin and Hydroxychloroquine for Chemo-Proph... 80% fewer cases (p<0.0001). Physician survey in India with 164 ivermectin prop...

**Stone** et al., Biologics... Changes in SpO2 on Room Air for 34 Severe COVID-1... Retrospective severe COVID-19 patients in Zimbabwe treated with ivermectin, d...

Lim et al., JAMA, doi.... Efficacy of Ivermectin Treatment on Disease Progress... 69% lower mortality (p=0.09), 59% lower ventilation (p=0.17), 22% lower ICU ad...

Rezk et al., Zagazig U... miRNA-223-3p, miRNA-2909 and Cytokines Expressi... 56% lower progression (p=0.06), 33% improved recovery (p=0.27), and 27% fast...

Verma et al., Indian J... Assessing Knowledge, Attitude, and Practices toward...

Survey of 306 healthcare workers involved in the medication of COVID-19 patien...

**Low** et al., Biochimica... Repositioning Ivermectin for Covid-19 treatment: Mol... Review of the antiviral characteristics of ivermectin and mechanisms of action. ...

**Borody** et al., TrialSite... Combination Therapy For COVID-19 Based on Iverme... 92% lower mortality (p=0.03) and 93% lower hospitalization (p<0.0001). Retrosp...

Segatori et al., Viruse... Effect of Ivermectin and Atorvastatin on Nuclear Loca... Gene expression analysis of nasopharyngeal swabs of COVID-19 positive and ne...

Jitobaom et al., Rese... Favipiravir and Ivermectin Showed in Vitro Synergistic... In Vitro study showing a strong synergistic effect of ivermectin and favipiravir. C...

Goodkin, M. Are Major Ivermectin Studies Designed for Failure?

Discussion of flaws in ivermectin trials creating a bias towards not finding an eff...

**Fordham** et al., OSF P... The uses and abuses of systematic reviews Analysis of defects in the Popp et al. meta analysis.

**Francés-Monerris** et ... Microscopic interactions between ivermectin and key... *In Silico* molecular dynamics study showing that ACE2 and ACE2/RBD aggregat...

TrialSite News Committed to Medical Evidence, a Prominent Iverme...

Report on Twitter's censorship of the British Ivermectin Recommendation Devel...

**Babalola** et al., Journ... A Randomized Controlled Trial of Ivermectin Monothe... Small RCT with 61 patients in Nigeria, all patients treated with ivermectin, zinc, ...

Mayer et al., Frontiers... Safety and Efficacy of a MEURI Program for the Use o... 55% lower mortality (p<0.0001) and 66% lower ICU admission (p<0.0001). Retro...

Scheim, D., TrialsSite ... Merck's deadly Vioxx playbook, redux: a debunked s... Discussion of Merck's ivermectin statements and past actions related to Vioxx r...

**Buonfrate** et al., Inter... High dose ivermectin for the early treatment of COVI... 20% improved viral clearance (p=0.59). Early terminated 89 patient RCT with 29 ...

Okogbenin et al., Nig... Clinical characteristics, treatment modalities and out...

Retrospective 300 COVID-19 patients in Nigeria treated with ivermectin, zinc, vit...

Marik et al., America... Ivermectin, A Reanalysis of the Data
Updated meta analysis showing no significant change if Elgazzar et al. is exclud...

**Neil** et al., American J... Bayesian Hypothesis Testing and Hierarchical Modeli... Updated Bayesian analysis of a subset of ivermectin trials showing that there is ...

**González-Paz** et al., B... Comparative study of the interaction of ivermectin wit... In Silico analysis of the components of ivermectin (avermectin-B1a and avermec...

González-Paz et al., J... Structural Deformability Induced in Proteins of Potenti... In Silico elastic network model analysis of ivermectin components (avermectin-...

Kory, P., Substack Summary of the Evidence for Ivermectin in COVID-19 Summary of the evidence base for ivermectin and COVID-19 including *in vitro* an...

Elavarasi et al., Lung I... Clinical features, demography, and predictors of outc... 20% lower mortality (p=0.12). Retrospective 2017 hospitalized patients in India, ...

Pedroso et al., The Br... Self-prescribed Ivermectin use is associated with a lo... Retrospective 45 healthcare workers in Brazil, showing lower creation of antibo...

La Pampa, Argentina La Pampa expondrá a la comunidad científica los res... 27% lower mortality and 38% lower combined mortality/ICU admission. News r...

Kow et al., American ... Pitfalls in Reporting Sample Size Calculation Across R... Review of sample size calculations in ivermectin RCTs, showing that existing RC...

Reis et al., New Engla... Effect of Early Treatment with Ivermectin among Pati... 12% lower mortality (p=0.68), 23% lower ventilation (p=0.38), 17% lower hospita...

Rana et al., Research ... A Computational Study of Ivermectin and Doxycycline... In silico study showing strong binding affinity of ivermectin and doxycycline for ...

Santin et al., New Mic... Ivermectin: a multifaceted drug of Nobel prize-honore... Review concluding that the evidence supports worldwide use of ivermectin for C...

Zein et al., Diabetes &... Ivermectin and mortality in patients with COVID-19: A...

61% lower mortality (p=0.005). Systematic review and meta analysis showing lo...

Sathi et al., Journal of... Clinical Effect of the Combination Therapy of Hydroxy... Prospective study of 85 COVID-19 patients including 8 ICU patients treated with ...

Popp et al., Cochrane... Ivermectin for preventing and treating COVID-19
This meta analysis is designed to exclude most studies. Authors select a small s...

Ontai et al., Epidemiol... Early multidrug treatment of SARS-CoV-2 (COVID-19) ... Report on the nationwide implementation of multi-drug COVID-19 inpatient and ...

World Ivermectin Day World Ivermectin Day Joint event by 22 worldwide organizations.

Mansour et al., Intern... Safety of inhaled ivermectin as a repurposed direct dr... Safety analysis of an inhaled lyophilized ivermectin formulation, showing 127-fol...

FLCCC Alliance and B... Joint Statement of the FLCCC Alliance and British Iver... News release noting that ivermectin remains effective after excluding Elgazzar e...

**Neil** et al., ResearchG... Bayesian Meta Analysis of Ivermectin Effectiveness in... Bayesian analysis of a subset of ivermectin trial data concluding that there is ov...

Muthusamy et al., Jo... Virtual Screening Reveals Potential Anti-Parasitic Dru... In Silico study identifying 32 anti-parisitic compounds effectively inhibiting the R...

Together Trial Together Trial removes sublingual administration mid...

Together Trial removes sublingual administration mid-trial.

Hazan et al., Future ... Effectiveness of ivermectin-based multidrug therapy i... 86% lower mortality (p=0.04) and 93% lower hospitalization (p=0.001). Small stu...

Open Letter, Stateme... Open Letter, Statement of Concern and Request for R... Open letter signed by 40 physicians detailing errors and flaws in the Roman et a...

Adegboro et al., Afric... A review of the anti-viral effects of ivermectin Review of the antiviral effects of ivermectin.

Vallejos et al., BMC In... Ivermectin to prevent hospitalizations in patients with...

33% lower hospitalization (p=0.23) and 5% worse viral clearance (p=0.55). RCT  $\dots$ 

Turkia, M., ResearchG... A Continuation of a Timeline of Ivermectin-Related Ev... An extension of the ivermectin timeline covering April - June 2021, including WH...

Roman et al., Clinical ... Ivermectin for the treatment of COVID-19: A systemat... This is a severely flawed meta analysis. An open letter signed by 40 physicians d...

**Jagiasi** et al., The Int... Variation in therapeutic strategies for the manageme... Survey of medication use for severe COVID-19 in India, showing 33% adoption o...

Misiones Ministry of ... Results from ivermectin use from the Misiones Minist...

News report on ivermectin use in Misiones, Argentina, showing significantly low...

Hayward et al., BMJ ... Platform Randomised trial of INterventions against C... Protocol paper for the PRINCIPLE trial. For the colchicine arm see [Dorward], for...

Lind et al., Journal of ... Increase in Outpatient Ivermectin Dispensing in the U... CDC analysis of ivermectin prescriptions in the US suggesting that, while nation...

**Krolewiecki** et al., eCl... Antiviral effect of high-dose ivermectin in adults with ... 66% improved viral load (p=0.09). Proof of concept RCT with 30 ivermectin patie...

Bryant et al., America... Ivermectin for Prevention and Treatment of COVID-19... 62% lower mortality (p=0.005). Systematic review, meta analysis, and trial seque...

**Munson** et al., British ... Niclosamide and ivermectin modulate caspase-1 acti... In Vitro study showing potential therapeutic effects of ivermectin and niclosami...

Aref et al., Internation... Clinical, Biochemical and Molecular Evaluations of Ive... 63% improved recovery (p=0.0001) and 79% improved viral clearance (p=0.004). ...

**Hariyanto** et al., Revie... Ivermectin and outcomes from Covid-19 pneumonia: ... 69% lower mortality (p=0.001). Systematic review and meta analysis of 19 RCTs ...

Wang et al., medRxiv,... Minimum manufacturing costs, national prices and e... Analysis of the manufacturing cost of several COVID-19 medications, showing a...

Abd-Elsalam et al., J... Clinical Study Evaluating the Efficacy of Ivermectin in ...

20% shorter hospitalization (p=0.09). RCT 164 hospitalized patients in Egypt sho...

Mondal et al., Journal... Prevalence of COVID-19 Infection and Identification of... 88% fewer symptomatic cases (p=0.006). Retrospective 1,470 healthcare worke...

Mountain Valley MD Mountain Valley MD Receives Successful Results Fro...

In Vitro and mouse study with human ACE2 cells, using solubilized ivermectin w...

FLCCC Public Statem... FLCCC Alliance Statement on the Irregular Actions of ...

Analysis of the ivermectin recommendations from WHO and others, and a call t...

**Faisal** et al., The Prof... Potential use of azithromycin alone and in combinatio... 68% improved recovery (p=0.005). RCT 100 outpatients in Pakistan, 50 treated ...

Zatloukal et al. News report on In Vitro results from the research insti...

News report on In Vitro results from the research institute of Prof. Zatloukal, sho...

Qureshi et al., Journa... Mechanistic insights into the inhibitory activity of FDA... In Silico study showing inhibition of importin-a1 by ivermectin, which disrupts S...

**Karale** et al., medRxiv... A Meta-analysis of Mortality, Need for ICU admission,... Systematic review and meta analysis with 30 studies included in quantitative an...

**Merino** et al., Preprint Ivermectin and the odds of hospitalization due to CO... 74% lower hospitalization (p=0.001). Analysis of Mexico City's use of an ivermec...

Moraes et al., NCT04... Comparative Study of Hydroxychloroquine and Iverm... Estimated 400 participant ivermectin vs. HCQ prophylaxis RCT with results not r...

**Kory** et al., American ... Review of the Emerging Evidence Demonstrating the ... Review of ivermectin trials and epidemiological data, concluding that ivermectin...

Ahsan et al., Cureus, ... Clinical Variants, Characteristics, and Outcomes Amo... 50% lower mortality (p=0.03). Retrospective 165 hospitalized patients in Pakista...

**DiNicolantonio** et al., ... Anti-inflammatory activity of ivermectin in late-stage ... Review suggesting that the effectiveness of ivermectin in the cytokine storm pha...

Loue et al., J. Infectio... Ivermectin and COVID-19 in Care Home: Case Report

70% lower mortality (p=0.34) and 55% lower severe cases (p=0.11). Small quasi-...

Morgenstern et al., C... Ivermectin as a SARS-CoV-2 Pre-Exposure Prophylaxi... 74% fewer cases (p=0.008). Propensity matched retrospective prophylaxis study...

Schöning et al., Rese... Highly-transmissible Variants of SARS-CoV-2 May Be ... In Silico study of ivermectin treatment predicting greater efficacy for variants wit...

**Seet** et al., Internation... Positive impact of oral hydroxychloroquine and povid... 50% fewer symptomatic cases (*p*=0.0009) and 6% fewer cases (*p*=0.61). Prophyl...

**Bello** et al., Journal of... Elucidation of the inhibitory activity of ivermectin with... *In Silico* analysis finding that the *in vitro* activity of ivermectin may explained by ...

Turkia, M., Research ... A timeline of ivermectin-related events in the COVID-1... An extensive timeline of ivermectin-related events from April 2020 to March 202...

**Mourya** et al., Interna... Comparative Analytical Study of Two Different Drug R... 89% improved viral clearance (p<0.0001). Retrospective 100 patients in India wit...

**Wehbe** et al., Front. I... Repurposing Ivermectin for COVID-19: Molecular Asp... Review of how ivermectin was identified for use in COVID-19, mechanisms of ac...

**Chahla** et al., Researc... Randomized trials - Ivermectin repurposing for COVID... 87% higher hospital discharge (p=0.004). Cluster RCT outpatients in Argentina s...

Kow et al., Pharmacol... The association between the use of ivermectin and m... Small meta analysis of 6 RCTs showing mortality OR 0.21 [0.11-0.42]. Authors d...

**Tanioka** et al., medRx... Why COVID-19 is not so spread in Africa: How does Iv... 88% lower mortality (p=0.002). Retrospective study of the 31 onchocerciasis-en...

**Udofia** et al., Network... In silico studies of selected multi-drug targeting again... In Silico analysis finding that ivermectin had the highest binding energy against t...

**Choudhury** et al., Fut... Exploring the binding efficacy of ivermectin against th... *In Silico* analysis finding that ivermectin has high binding affinity for the SARS-C...

Huvemek, Press Rele... Kovid-19 - Huvemek® Phase 2 clinical trial

32% greater improvement (p=0.28). Multicenter double-blind RCT with 100 hosp...

Yagisawa et al., The J... Global trends in clinical studies of ivermectin in COVI... Review of ivermectin for COVID-19. Authors note that Kitasato University's proje...

Emmerich et al., Int. J... Comparisons between the Neighboring States of Am... Comparison between the two largest neighboring states in Brazil, Amazonas an...

Del Franco et al., Jou... Ivermectin in Long-Covid Patients: A Retrospective St... Retrospective 856 patients previously admitted to hospital for COVID-19 in Arge...

**Dinesh Kumar** et al., ... Moxidectin and ivermectin inhibit SARS-CoV-2 replica... *In Vitro* study showing moxidectin and ivermectin exhibited antiviral activity in V...

Roy et al., medRxiv, d... Outcome of Different Therapeutic Interventions in Mil... 6% faster recovery (p=0.87). Retrospective database analysis of 56 mild COVID-...

**Nardelli** et al., Signa ... Crying wolf in time of Corona: the strange case of iver... 79% lower mortality (p<0.0001). Meta analysis of RCT mortality results showing ...

Scheim et al., OSF Pr... Ivermectin sales in Valle del Cauca, Colombia, patter... Analysis of several issues with López-Medina et al. including the atypical advers...

Scheim et al., OSF Pr... Protocol violations in López-Medina et al.: 38 switche... Report on protocol violations in López-Medina et al.

**Kern** et al., Frontiers i... Modeling of SARS-CoV-2 Treatment Effects for Infor... Modeling study analyzing timing and dosing regimens of hydroxychloroquine, lo...

**Yesilbag** et al., Virus ... Ivermectin also inhibits the replication of bovine respi... *In Vitro* study showing that ivermectin can inhibit infection of bovine respiratory ...

Pott-Junior et al., Tox... Use of ivermectin in the treatment of Covid-19: a pilot... 85% lower ventilation (p=0.25), 85% lower ICU admission (p=0.25), and 1% impr...

**Chamie-Quintero** et a... Ivermectin for COVID-19 in Peru: 14-fold reduction in ... Analysis of ivermectin use in Peru concluding that ivermectin most likely caused...

Guzman et al., medR... Factors associated with increased mortality in critical...

19% lower mortality (p=0.35). Retrospective 196 critically ill patients in Mexico. ...

Galan et al., Pathoge... Phase 2 randomized study on chloroquine, hydroxych... RCT 168 very late stage severe condition hospitalized patients comparing CQ, H...

**Descotes**, J., Immun... Medical Safety of Ivermectin
Safety analysis of >350 articles showing that ivermectin has an excellent safety ...

**López-Medina** et al., ... Effect of Ivermectin on Time to Resolution of Sympto... 61% lower progression (p=0.11) and 15% improved recovery (p=0.53). Phone sur...

Saha et al., Structural... The Binding mechanism of ivermectin and levosalbut... In Silico analysis predicting that ivermectin has a large binding affinity for the SA...

Beltran Gonzalez et a... Efficacy and Safety of Ivermectin and Hydroxychloroq... 14% lower mortality (p=1), 9% lower progression (p=1), 37% lower hospital disc...

BIRD Meeting 20th Fe... BIRD Meeting 20th February 2021

The British Ivermectin Recommendation Development (BIRD) panel, with dozens...

**Elalfy** et al., Journal o... Effect of a combination of Nitazoxanide, Ribavirin and... 87% improved viral clearance (p<0.0001). Non-randomized controlled trial with 6...

Behera et al., Cureus,... Prophylactic Role of Ivermectin in Severe Acute Respir... 83% fewer cases (p=0.001). Prospective prophylaxis study with 3,532 healthcare...

Biber et al., Internatio... The effect of ivermectin on the viral load and culture v... 70% lower hospitalization (p=0.34) and 62% improved viral clearance (p=0.02). D...

Lima-Morales et al., I... Effectiveness of a multidrug therapy consisting of iver... 78% lower mortality (p=0.001), 52% lower ventilation (p=0.15), 67% lower hospit...

Mohan et al., Journal ... Single-dose oral ivermectin in mild and moderate CO... 62% improved recovery (p=0.27) and 24% improved viral clearance (p=0.18). RC...

Jans et al., Biochemi... The broad spectrum host-directed agent ivermectin a... Review of the potential of ivermectin as an antiviral against SARS-CoV-2 and CO...

Cobos-Campos et al.... Potential use of ivermectin for the treatment and profi...

Review finding that there appears to be sufficient evidence to recommend iverm...

Castaneda-Sabogal ... Outcomes of Ivermectin in the treatment of COVID-19... Meta analysis of a very small subset of studies exhibiting very high bias and sign...

**Eweas** et al., Frontier... Molecular Docking Reveals Ivermectin and Remdesivi... Molecular docking analysis showing that ivermectin efficiently binds to the viral ...

**Errecalde** et al., Jour... Safety and Pharmacokinetic Assessments of a Novel I... Animal study of a novel spray formulation of ivermectin, showing an advantage ...

**Chamie-Quintero** et a... Sharp Reductions in COVID-19 Case Fatalities and Ex... Analysis of ivermectin usage within states in Peru showing sharp reductions in ...

Mody et al., Commun... Identification of 3-chymotrypsin like protease (3CLPr... Computational molecular modeling screening and *in vitro* analysis for inhibitory ...

Shahbaznejad et al., ... Effects of Ivermectin in Patients With COVID-19: A Mu... 32% faster recovery (p=0.05) and 15% shorter hospitalization (p=0.02). RCT in Ir...

Hill et al., Research S... Meta-analysis of randomized trials of ivermectin to tr... 75% lower mortality (p=0.0002). Meta analysis of 18 ivermectin RCTs with 2,282...

Samaha et al., Viruse... Effects of a Single Dose of Ivermectin on Viral and Cli... This study was retracted.

**Bukhari** et al., medRxi... Efficacy of Ivermectin in COVID-19 Patients with Mild ... 82% improved viral clearance (p<0.0001). RCT of relatively low risk hospitalized ...

Kory et al., Frontiers i... Review of the Emerging Evidence Demonstrating the ... Meta analysis of ivermectin clinical studies and natural experiments where iver...

Okumuş et al., BMC I... Evaluation of the Effectiveness and Safety of Adding I... 33% lower mortality (p=0.55), 43% greater improvement (p=0.18), and 80% impr...

Chahla et al., Americ... Intensive Treatment With Ivermectin and Iota-Carrage... 95% fewer moderate/severe cases (p=0.002) and 84% fewer cases (p=0.004). Pr...

Bousquet-Mélou et al... A Large Impact of Obesity on the Disposition of Iverm...

Animal dosing study with an obese dog model concluding that ivermectin maint...

Formiga et al., J. Con... Ivermectin: an award-winning drug with expected ant... Review hypothesizing that micro- and nanotechnology-based formulations of iv...

Ravikirti et al., Journa... Ivermectin as a potential treatment for mild to moder... 89% lower mortality (p=0.12), 79% lower ventilation (p=0.1), 14% lower ICU adm...

Chamie, J. COVID-19 in Mexico

Comparison of COVID-19 death rates in Mexico showing that the only state usin...

Babalola et al., QJM: ... Ivermectin shows clinical benefits in mild to moderat... 64% improved viral clearance (p=0.11) and 41% improved recovery (p=0.07). Sm...

Hirsch et al., Microbi... Ivermectin as Prophylaxis Against COVID-19 Retrospe... Report on ivermectin prophylaxis for healthcare workers in a hospital in Argentin...

Lawrie et al., Preprint Ivermectin reduces the risk of death from COVID-19 –... 83% lower mortality (p<0.0001). Meta analysis confirming the effectiveness of iv...

Wijaya et al., Cermin ... Ivermectin as a Potential Therapeutic Agent for COVI... Case report on 3 confirmed cases of COVID-19 with significant clinical and radi...

**Madrid** et al., Heliyon,... Safety of oral administration of high doses of ivermec... *In vivo* analysis of the safety of high dose ivermectin with a Corydoras fish anim...

Scheim, D., SSRN, doi... Ivermectin for COVID-19 Treatment: Clinical Respons... Review of ivermectin for COVID-19 treatment and a hypothesized mechanism of...

McCullough et al., Re... Multifaceted highly targeted sequential multidrug tre... Review urging early treatment of COVID-19 with sequential multidrug treatment ...

Procter et al., Review... Clinical outcomes after early ambulatory multidrug th... Retrospective 922 outpatients, with 320 treated early due to age>50 or comorbi...

Hill, A., Preprint Meta-analysis of clinical trials of ivermectin to treat C...
WHO-funded meta analysis showing ivermectin treatment mortality relative risk ...

Jeffreys et al., Interna... Remdesivir-ivermectin combination displays synergist...

In Vitro study showing enhanced antiviral activity of ivermectin and remdesivir in...

IVERCOR PREP, Preli... Ivermectina en agentes de salud e IVERCOR COVID19 73% fewer cases (p<0.0001). Report on ivermectin prophylaxis in a hospital in Ar...

Kory et al., FLCCC Alli... Review of the Emerging Evidence Demonstrating the ... 69% lower mortality (p<0.0001). Meta analysis of ivermectin clinical studies and ...

Alam et al., European ... Ivermectin as Pre-exposure Prophylaxis for COVID-19 ... 91% fewer cases (p<0.0001). 91% reduction in COVID-19 cases with ivermectin ...

**Ghauri** et al., Internati... Ivermectin Use Associated with Reduced Duration of ... 92% improved recovery (p=0.04). Retrospective 95 outpatients in Pakistan with s...

**Hussain** et al., Interna... Outcome of ivermectin and doxycycline in cancer pati... Small case study of ivermectin + doxycycline with 8 cancer patients, with all pati...

Chaccour et al., eClini... The effect of early treatment with ivermectin on viral l... 96% improved symptoms (p=0.05), 95% improved viral load (p=0.01), and 8% im...

Kalfas et al., medRxiv,... The therapeutic potential of ivermectin for COVID-19: ... Review of ivermectin mechanisms and 8 trials, showing positive mortality benefi...

Surnar et al., ACS Ph... Clinically Approved Antiviral Drug in an Orally Adminis... In Vitro analysis of ivermectin with orally administrable nanoparticles showing ef...

Ahmed et al., Internat... A five day course of ivermectin for the treatment of C... 85% improved symptoms (p=0.09), 76% improved viral clearance (p=0.03), and ...

Chamie, J. The effect of using ivermectin to control COVID-19 in ... Report showing that after starting to distribute ivermectin in drug kits in July, th...

Alonso et al., Correa ... COVID-19: Uso de ivermectina 92% lower mortality (p=0.009). Observational study in Argentina showing signifi...

Parvez et al., Internati... Prediction of potential inhibitors for RNA-dependent R... In Silico study showing that ivermectin, rifabutin, rifapentine, fidaxomicin, and 7...

Ma et al., Biomedicin... Ivermectin contributes to attenuating the severity of a...

Animal study showing dose dependent inhibition of lung injury with ivermectin. I...

**Bernigaud** et al., Ann... Ivermectin benefit: from scabies to COVID-19, an exa... 99% lower mortality (p=0.08) and 55% fewer cases (p=0.01). 69 residents of a Fr...

Hellwig et al., Interna... A COVID-19 Prophylaxis? Lower incidence associated... 78% fewer cases (p=0.02). Analysis of COVID-19 cases vs. widespread prophyla...

Niaee et al., Asian Pa... Ivermectin as an adjunct treatment for hospitalized a... 82% lower mortality (p=0.001). 82% lower mortality with ivermectin. RCT with 1...

**de Melo** et al., EMBO ... Attenuation of clinical and immunological outcomes ... Animal study showing that standard doses of ivermectin prevented clinical deter...

**Budhiraja** et al., med... Clinical Profile of First 1000 COVID-19 Cases Admitte... 99% lower mortality (p=0.04). Retrospective 976 hospitalized patients with 34 tr...

**Carvallo** et al., Journ... Study of the Efficacy and Safety of Topical Ivermectin ... 100% fewer cases (p<0.0001). Prophylaxis study using ivermectin and iota-carra...

**Spoorthi** et al., IAIM, ... Utility of Ivermectin and Doxycycline combination for ... 21% faster recovery (p=0.03) and 16% shorter hospitalization (p=0.01). 100 patie...

**Elgazzar** et al., Resea... Efficacy and Safety of Ivermectin for Treatment and p... This study was withdrawn.

**Camprubí** et al., PLoS... Lack of efficacy of standard doses of ivermectin in se... 40% lower ventilation (p=0.67), 33% lower ICU admission (p=1), 33% worse impr...

Turkia, M., ResearchG... FLCCC Alliance MATH+ ascorbic acid and I-MASK+ iv... Review suggesting that ivermectin should be used based on existing data sugge...

**Cadegiani** et al., New... Early COVID-19 Therapy with azithromycin plus nitaz... 94% lower ventilation (*p*=0.005) and 98% lower hospitalization (*p*<0.0001). **Com...** 

**Morgenstern** et al., J.... The Use of Compassionate Ivermectin in the Manage... Retrospective 3,099 outpatients treated with ivermectin in an ER. Of 2,706 treat...

Behera et al., PLOS O... Role of ivermectin in the prevention of SARS-CoV-2 inf...

54% fewer cases (p=0.0007). Retrospective matched case-control prophylaxis st...

Arévalo et al., Scientif... Ivermectin reduces in vivo coronavirus infection in a ... Mouse study showing ivermectin reducing MHV viral load and disease. MHV is ...

Chang et al., Researc... COVID-19: Effectiveness of pre-exposure prophylaxis ... Pre-exposure prophylaxis study with 129 people split into high/low exposure gro...

Szente Fonseca et al.... Risk of Hospitalization for Covid-19 Outpatients Treat... 14% higher hospitalization (p=0.53). Retrospective 717 patients in Brazil showin...

**Hashim** et al., Iraqi Jo... Controlled randomized clinical trial on using Ivermecti... 92% lower mortality (p=0.03), 83% lower progression (p=0.07), and 41% faster r...

Guerrero et al., Colo... COVID-19: The Ivermectin African Enigma
Study of African Programme for Onchocerciasis Control (APOC) countries, whic...

**Carvallo** et al., NCT04... Usefulness of Topic Ivermectin and Carrageenan to P... 96% fewer cases (p<0.0001). Prophylaxis study using ivermectin and carrageena...

Chaccour et al., Scien... Nebulized ivermectin for COVID-19 and other respirat... Study showing that nebulized ivermectin can reach pharmacodynamic concentr...

Rajter et al., Chest, d... Use of Ivermectin is Associated with Lower Mortality i... 46% lower mortality (p=0.05) and 64% lower ventilation (p=0.1). Retrospective 2...

Mahmud et al., Journ... Ivermectin in combination with doxycycline for treatin... 86% lower mortality (p=0.25), 57% lower progression (p=0.001), 94% improved r...

Francés-Monerris et ... Has Ivermectin Virus-Directed Effects against SARS-C... In silico study showing that ivermectin is capable of interfering in different key st...

**Soto-Becerra** et al., ... Real-World Effectiveness of hydroxychloroquine, azith... 17% lower mortality (p=0.01). Retrospective database study of 5683 patients, 6...

Chachar et al., Intern... Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 ... 10% improved recovery (p=0.5). Small RCT with 25 ivermectin and 25 control pa...

Kalhor et al., Journal ... Repurposing of the approved small molecule drugs in...

In Silico study showing favorable binding of several FDA-approved drugs to the ...

Khan et al., Archivos ... Ivermectin treatment may improve the prognosis of p... 87% lower mortality (p=0.02), 89% lower ICU admission (p=0.007), 83% lower pr...

Li et al., J. Cellular Ph... Quantitative proteomics reveals a broad-spectrum an... In Vitro study showing Ivermectin is a safe wide-spectrum antiviral against SARS...

**Carvallo** et al., Journ... Safety and Efficacy of the Combined Use of Ivermecti... 85% lower mortality (p=0.08). Prospective trial of ivermectin, dexamethasone, e...

Jans et al., Cells 202... Ivermectin as a Broad-Spectrum Host-Directed Antivir... Review of ivermectin as a host-directed broad-spectrum antiviral agent for a ran...

**Elkholy** et al., Cureus,... Ivermectin: A Closer Look at a Potential Remedy Proposal to use inhaled ivermectin for COVID-19. Author notes that ivermectin ...

Swargiary, A., Resear... Ivermectin as a promising RNA-dependent RNA poly... In Silico study showing high binding affinity of ivermectin with SARS-CoV-2 RNA-...

**DiNicolantonio** et al., ... Ivermectin may be a clinically useful anti-inflammator... Review suggesting that ivermectin may be useful for late stage COVID-19. Autho...

Podder et al., IMC J. ... Outcome of ivermectin treated mild to moderate COV... 16% faster recovery (p=0.34). Small RCT with 32 ivermectin patients and 30 con...

Kamal et al., NCT044... Ivermectin In Treatment of COVID 19 Patients
Estimated 100 patient ivermectin early treatment RCT with results not reported ...

**Kishoria** et al., Paripe... Ivermectin as adjuvant to hydroxychloroquine in patie... 8% lower hospital discharge (p=1) and 8% worse viral clearance (p=1). Small RC...

Shouman et al., Jour... Use of Ivermectin as a Potential Chemoprophylaxis fo... 91% fewer symptomatic cases (p=0.001) and 93% lower severe cases (p=0.002)....

Espitia-Hernandez et... Effects of Ivermectin-azithromycin-cholecalciferol co... 70% faster recovery (p=0.0001) and 97% improved viral clearance (p<0.0001). S...

Bhattacharya et al., I... Observational Study on Clinical Features, Treatment a...

Retrospective 148 hospitalized patients showing triple therapy with ivermectin +...

Vora et al., Indian Jou... White paper on Ivermectin as a potential therapy for ... Panel review of ivermectin reporting that "ivermectin in the dose of 12mg BD alo...

**Chang** et al., Researc... Post-acute or prolonged COVID-19: ivermectin treatm... Report on 33 patients with persistent or post-acute symptoms treated with iver...

**Chang** et al., Researc... COVID-19: Post-exposure prophylaxis with ivermectin... Proposed PEP protocol based on ivermectin.

Alam et al., Journal of... A Case Series of 100 COVID-19 Positive Patients Trea... Case study of 100 patients treated with ivermectin and doxycycline, with no ICU...

Rahman et al., J. Ban... Comparison of Viral Clearance between Ivermectin wi... Comparison of 200 patients treated with ivermectin + doxycycline and 200 treat...

Chang et al., Researc... COVID-19: Ivermectin Prophylaxis in Adult Contacts: ... Report on ivermectin post-exposure prophylaxis with 33 patients, showing no c...

Chowdhury et al., Eur... A Comparative Study on Ivermectin-Doxycycline and ... 81% lower hospitalization (p=0.23), 46% improved recovery (p<0.0001), and 81...

Maurya, D., American... A Combination of Ivermectin and Doxycycline Possibl... In Silico study showing that a combination of ivermectin and doxycycline may in...

**Gorial** et al., medRxiv,... Effectiveness of Ivermectin as add-on Therapy in COV... 42% shorter hospitalization (p<0.0001). Small trial of hospitalized patients with ...

**Lehrer** et al., In Vivo, ... Ivermectin Docks to the SARS-CoV-2 Spike Receptor-... *In silico* analysis showing ivermectin may interfere with the attachment of the sp...

Ramos et al., Preprint Intervención de la Ivermectina Pre-Hospitalaria para I...

Prospective study of 63 outpatients in Peru treated with ivermectin, reporting si...

**Heidary** et al., The Jo... Ivermectin: a systematic review from antiviral effects ... Review of the antimicrobial, antiviral, and anti-cancer properties of ivermectin. A...

Suravajhala et al., Pre... Comparative Docking Studies on Curcumin with COVI...

In Silico study reporting that ivermectin had the best affinity towards all targeted...

Arshad et al., Clinical ... Prioritization of Anti-SARS-Cov-2 Drug Repurposing O... Pharmacokinetic analysis predicting that ivermectin, HCQ, CQ, and azithromyci...

Chang, G., Research ... Inclusión de la ivermectina en la primera línea de acci... Peru observational case study of 7 patients treated with ivermectin, showing im...

**Bray** et al., Antiviral R... Ivermectin and COVID-19: A report in Antiviral Resear... Responses to Caly et al., and the author's reply. The original authors note that "i...

Caly et al., Antiviral R... The FDA-approved drug ivermectin inhibits the replica... In Vitro study showing that ivermectin is an inhibitor of SARS-CoV-2, with a singl...

Areskog et al., Veteri... Dexamethasone treatment interferes with the pharm...

Analysis of ivermectin and dexamethasone treatment in cattle, showing that dex...

Yan et al., Inflammati... Anti-inflammatory effects of ivermectin in mouse mo... Mouse study showing ivermectin significantly reduced airway inflammation, Th2...

**Zhang** et al., Inflamm... Ivermectin inhibits LPS-induced production of inflam... Analysis of ivermectin's effects in mouse models of lethal endotoxemia, which ...

**Lespine** et al., Veterin... Influence of the route of administration on efficacy an... Pharmacokinetic analysis of ivermectin in goats, showing that tissue concentrat...

Guzzo et al., J. Clinica... Safety, Tolerability, and Pharmacokinetics of Escalatin... Safety study concluding that ivermectin was generally well tolerated, with no ind...

Lifschitz et al., Veteri... Comparative distribution of ivermectin and doramecti... Pharmacokinetic analysis of ivermectin in cattle, showing that tissue concentrat...

**Chiu** et al., J. Agric. F... Absorption, tissue distribution, and excretion of tritiu... Animal study showing that lung tissue concentration of ivermectin may be ~20 t...

For search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), PRISMA answers, and statistical methods see methods. Studies with preprints and journal versions are listed under the earlier preprint date.

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Feedback			

Submit